Global Cardiovascular Disease Market 2017 - Robust Pipeline with Attempts to Meet Unmet Need
DUBLIN, Dec. 6, 2017 /PRNewswire/ --
The "Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis" drug pipelines has been added to Research and Markets' offering.
Cardiovascular disease (CVD) is a broad therapy area containing a range of indications relating to the human vasculature, heart and lipid levels. There is considerable first-in-class innovation within the CVD pipeline, comparable with the industry average. The molecular target groups with the highest proportion of first-in-class products include lipid metabolism, transmembrane and extracellular signaling, intracellular signal transduction and ion channels.
Of the four key CVD indications identified in this report (hypertension, heart failure, dyslipidemia and thrombosis), the hypertensive pipeline is the largest, with 238 products in development. The pipelines for heart failure and dyslipidemia are also large. Drugs in development for thrombosis, and specifically the treatment or prevention of thrombosis itself (as opposed to managing the underlying risk factors) has a relatively small pipeline of just 104 products. Overall, there are 1,400 plus products in the CVD pipeline.
There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market, first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of PCSK9 inhibitors. Innovation continues within the dyslipidemia pipeline, The most promising first-in-class development within dyslipidemia focuses on targeting elements of the reverse lipid transport pathway. This is the process of high density lipoproteins (HDL) collecting cholesterol from cells, such as macrophages within atherosclerotic plaques, for removal from circulation in the liver via receptors such as scavenger receptor class B member 1 (SRB1).
Conventional classes of molecular target within the treatment of CVD are now showing relatively low levels of development, as innovation moves towards diverse targets related to the immune system, and transmembrane and extracellular signaling - with transmembrane proteins being a prominent source of innovation within the CVD pipeline.
This report has been designed to identify innovative pipeline programs across a therapy area with a focus on indications with high R&D activity and strong innovation, as well as a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming an increasingly vital part of competitive intelligence for all market participants, and increasingly important for companies seeking strategic partnerships or looking to acquire technologies, products or other companies.
Scope
- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?
- There are 320 first-in-class products in the CVD market that act on a novel molecular target thatis not present in an approved product across any indication in the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?
Key Topics Covered:
1 Table of Contents
2 Executive Summary
2.1 Robust pipeline with attempts to meet unmet need
2.2 Drugs targeting apolipoproteins and elements of the reverse lipid transport pathway offer potential new therapies for the treatment of dyslipidemia and atherosclerosis
2.3 Cardiovascular disease pipeline emphasizes move away from conventional areas towards targets related to transmembrane and extracellular signaling
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation in Cardiovascular Disease
3.6 Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Cardiovascular Disease Overview
4.2 Symptoms, Disease Staging and Prognosis
4.3 Diagnosis
4.4 Epidemiology
4.5 Etiology and Pathophysiology
4.6 Management and Treatment of Cardiovascular Disease
4.7 Overview of Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
5.5 First-in-Class Programs Targeting Novel Molecular Targets
6 Signaling Network and Innovation Alignment within Cardiovascular Disease
6.1 Complexity of Signaling Networks in Cardiovascular Disease
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment
7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Apelin Receptor
7.2 Pipeline Programs Targeting Apolipoproteins (Apolipoprotein E, Apolipoprotein C-III and Apolipoprotein A-I)
7.2.1 APOE
7.2.2 APOCIII
7.2.3 ApoA1
7.3 Pipeline Programs Targeting Scavenger Receptor Class B Member 1 (SRB1)
7.4 Pipeline Programs Targeting Cholesteryl Ester Transfer Protein (CETP)
7.5 Pipeline Programs Targeting Glutamyl Aminopeptidase
7.6 Pipeline Programs Targeting E-selectin
7.7 Pipeline Programs Targeting Platelet Glycoproteins (Platelet Glycoprotein VI and Platelet Glycoprotein Ib Alpha Chain)
7.7.1 Platelet Glycoprotein VI (GP6)
7.7.2 Platelet Glycoprotein Ib Alpha Chain (GP1ba)
7.8 Pipeline Programs Targeting Tissue Factor
7.9 Conclusion
8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals
9 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mfzjf9/frontier_pharma
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article